1208 related articles for article (PubMed ID: 29284708)
1.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
2. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
3. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.
Rossi G; Mu Z; Rademaker AW; Austin LK; Strickland KS; Costa RLB; Nagy RJ; Zagonel V; Taxter TJ; Behdad A; Wehbe FH; Platanias LC; Gradishar WJ; Cristofanilli M
Clin Cancer Res; 2018 Feb; 24(3):560-568. PubMed ID: 29180605
[No Abstract] [Full Text] [Related]
4. Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.
Parisi C; Mastoraki S; Markou A; Strati A; Chimonidou M; Georgoulias V; Lianidou ES
Clin Chim Acta; 2016 Oct; 461():156-64. PubMed ID: 27510924
[TBL] [Abstract][Full Text] [Related]
5. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
[No Abstract] [Full Text] [Related]
6. Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
Paoletti C; Schiavon G; Dolce EM; Darga EP; Carr TH; Geradts J; Hoch M; Klinowska T; Lindemann J; Marshall G; Morgan S; Patel P; Rowlands V; Sathiyayogan N; Aung K; Hamilton E; Patel M; Armstrong A; Jhaveri K; Im SA; Iqbal N; Butt F; Dive C; Harrington EA; Barrett JC; Baird R; Hayes DF
Clin Cancer Res; 2018 Dec; 24(23):5860-5872. PubMed ID: 30082476
[TBL] [Abstract][Full Text] [Related]
7. Detection of Activating Estrogen Receptor Gene (
Paolillo C; Mu Z; Rossi G; Schiewer MJ; Nguyen T; Austin L; Capoluongo E; Knudsen K; Cristofanilli M; Fortina P
Clin Cancer Res; 2017 Oct; 23(20):6086-6093. PubMed ID: 28679775
[No Abstract] [Full Text] [Related]
8. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
Sundaresan TK; Dubash TD; Zheng Z; Bardia A; Wittner BS; Aceto N; Silva EJ; Fox DB; Liebers M; Kapur R; Iafrate J; Toner M; Maheswaran S; Haber DA
Breast Cancer Res Treat; 2021 Jul; 188(1):43-52. PubMed ID: 34101078
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
Spiliotaki M; Kallergi G; Nikolaou C; Xenidis N; Politaki E; Apostolaki S; Georgoulia N; Koinis F; Tsoukalas N; Hatzidaki D; Kotsakis A; Georgoulias V
Cancer Chemother Pharmacol; 2021 Feb; 87(2):277-287. PubMed ID: 33515073
[TBL] [Abstract][Full Text] [Related]
12.
Stergiopoulou D; Markou A; Tzanikou E; Ladas I; Makrigiorgos GM; Georgoulias V; Lianidou E
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535614
[TBL] [Abstract][Full Text] [Related]
13. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Kruger DT; Jansen MPHM; Konings IRHM; Dercksen WM; Jager A; Oulad Hadj J; Sleijfer S; Martens JWM; Boven E
Mol Oncol; 2020 Mar; 14(3):490-503. PubMed ID: 31841262
[TBL] [Abstract][Full Text] [Related]
14. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
15. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
Franken A; Honisch E; Reinhardt F; Meier-Stiegen F; Yang L; Jaschinski S; Esposito I; Alberter B; Polzer B; Huebner H; Fasching PA; Pancholi S; Martin LA; Ruckhaeberle E; Schochter F; Tzschaschel M; Hartkopf AD; Mueller V; Niederacher D; Fehm T; Neubauer H
J Mol Diagn; 2020 Jan; 22(1):111-121. PubMed ID: 31669227
[TBL] [Abstract][Full Text] [Related]
16. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
Gerratana L; Davis AA; Polano M; Zhang Q; Shah AN; Lin C; Basile D; Toffoli G; Wehbe F; Puglisi F; Behdad A; Platanias LC; Gradishar WJ; Cristofanilli M
Eur J Cancer; 2021 Jan; 143():147-157. PubMed ID: 33307492
[TBL] [Abstract][Full Text] [Related]
17. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
19. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
20. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
Giannopoulou L; Mastoraki S; Buderath P; Strati A; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Gynecol Oncol; 2018 Aug; 150(2):355-360. PubMed ID: 29807696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
